Member Info for elrico

https://www.facebook.com/gofigurediet/

Neurologist Speaks Out About the Importance of Gut Health for Prevention and Treatment of “Incurable” Neurological Disorders. extract; They manufacture important vitamins that are important to keep your brain healthy. They also maintain the integrity of the lining of your gut,” he explains. The latter is important because when your gut lining becomes compromised, you end up with permeability or leakiness of the gut. This increases inflammation, which is a cornerstone of virtually all brain disorders, from Alzheimer’s and multiple sclerosis (MS), to Parkinson’s and autism. “We’ve got to really deal with it on a preventive basis,” Dr. Perlmutter says. “[We must] understand what in our Western culture, especially from a dietary perspective, is threatening the health of our commensals. We call these bacteria ‘commensals’ because they share the table with us. We eat together with the bacteria. Basically, they eat what we eat. Our food choices have a dramatic effect on the health viability and even the diversity of those gut bacteria.” https://tinyurl.com/ya5vxhtj

If it was he would say 24 hours before he intended. Like him or loath, you can't fault his integrity, unless he called a short on your long.

Interims from Optibiotix (AIM: OPTI) mark the start of its transition from R&D house into a commercial business. The company is developing supplements and ingredients which have a desirable physical effect by modifying the human microbiome – the collection of microbes in the body. Potential markets are massive, with products focused on managing cholesterol, obesity and diabetes. Optibiotix aims to generate royalty and license income from partners, who will use its active ingredients in products that they will manufacture and market.PartnershipsManagement has been successful in concluding a number of deals with good quality partners, following the launch of its first formulations. It’s now all about turning these agreements into revenue streams. For example it has partnered with Tata Chemicals for weight loss products in India. Deals for its LD-LPL cholesterol product are in place with Germany’s HLH Biopharma for distribution to pharmacies and with Sacco, a leading European manufacturer of probiotic ingredients. Other agreements are in place and we should expect continued news flow in this sphere.Show me the moneyHowever news of deals isn’t enough on its own to move the shares forward from the 60-80p range they’ve occupied for a couple of years now. The market will want to see revenue being generated from them and to get a real sense of how big both the existing products and the ones in the pipeline could be. We know their addressable markets are huge – but will they be successful in winning share? The company says it can ‘see a path to revenues of £5-6 million plus a year for each of its products in the near future’.No forecastsUnfortunately there are no forecasts in the market from company broker finnCap. The company hasn’t issued any guidance, which makes sense to some extent: no point in putting yourselves under pressure to meet targets when you don’t really know how quickly things will progress. Even so a ‘guesstimate’ from the broker would be nice. All we can say is that a £55 million market cap doesn’t look unreasonable given the size of the market and leaves scope for significant upside if all goes well.Cash ended May at £1.9 million. While the company has expanded its headcount as it moves into the next phase, it operates a royalty model and doesn’t have to fund manufacturing or the sales and marketing of end products to consumers. This capital-lite approach means management say current cash is ‘sufficient to cover the delivery of existing development and commercial plans’. http://www.growthcompany.co.uk/wyg-halves-profit-warning-2556502/

https://www.biospace.com/News/optibiotix-agrees-scale-up-and-manufacturing-deal/468492/source=MoreNews The url was in the post.

From a more reliable, reputable source that does not out of date science from 13 years ago. For years, we thought of bacteria as organisms to avoid. It turns out our bodies are already loaded with trillions of bacteria. They help digest food and play an important role in your well-being. Research suggests your gut bacteria are tied to your probability of things like diabetes, obesity, depression, and colon cancer. What Are Gut Bacteria? Living inside of your gut are 300 to 500 different kinds of bacteria containing nearly 2 million genes. Paired with other tiny organisms like viruses and fungi, they make what’s known as the microbiota, or the microbiome. Like a fingerprint, each person's microbiota is unique: The mix of bacteria in your body is different from everyone else's mix. It’s determined partly by your mother’s microbiota -- the environment that you’re exposed to at birth -- and partly from your diet and lifestyle. The bacteria live throughout your body, but the ones in your gut may have the biggest impact on your well-being. They line your entire digestive system. Most live in your intestines and colon. They affect everything from your metabolism to your mood to your immune system. Gut Bacteria and Disease Research suggests the gut bacteria in healthy people are different from those with certain diseases. People who are sick may have too little or too much of a certain type. Or they may lack a wide variety of bacteria. It’s thought some kinds may protect against ailments, while others may raise the risk. Scientists have begun to draw links between the following illnesses and the bacteria in your gut: Obesity, type 2 diabetes, and heart disease: Your gut bacteria affect your body’s metabolism. They determine things like how many calories you get from food and what kinds of nutrients you draw from it. Too much gut bacteria can make you turn fiber into fatty acids. This may cause fat deposits in your liver, which can lead to something called “metabolic syndrome” -- a condition that often leads to type 2 diabetes, heart disease, and obesity. Inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis: People with these conditions are believed to have lower levels of certain anti-inflammatory gut bacteria. The exact connection is still unclear. But it’s thought that some bacteria may make your body attack your intestines and set the stage for these diseases. https://www.biospace.com/News/optibiotix-agrees-scale-up-and-manufacturing-deal/468492/source=MoreNews

What has a pharmaceutical (Ibuprofen) got to do with GRAS related products? SweetBiotix, as an example, is a non digestible fibre that can replace sugar and stevia. Are you seriously attempting to suggest Reading University's study is flawed?

Best get onto Reading University and explain to them where they're going wrong with PROVING OPTI's the science.

No problem. You're not the first to raise the same question today. I can't pretend I know the regulatory statutes, as there's so many of them....especially when the EU get involved. All I know for sure is OPTI's science is classed as GRAS and are backed by science. There are so many FC added to supplements and food making wild unsubstantiated claims, OPTI cannot be placed in that bracket. The FDA have been clamping down of probiotic claims, so OPTI have already prepared the science for the US market, in this respect - Or at least that is my understanding.

It is regulated, FDA stateside, EU commision. There lots of legislation on bacterial foodstuffs. OPTI's science is accepted Generally recognized as safe (GRAS).

And yet he did not realise this was a completely new deal, which had to be pointed out to him, hence the quick update the next morning.

This low volume....is actually above normal market volume. Ignorant as ignorant can be on the very basics. I like the trading strategy though. It's just a shame every Walter Mitty type talks a good trade, when the reality is, 80+% get it wrong. Not my stats, FCA stats no less. Next joke please.

No idea. Ignore me :) https://goo.gl/TM3VhJ

Extract from an article I wrote yesterday. TATA commercialisation It is worth finishing off with a few observations regarding Tuesdays announcement TATA will be running one month “pilot trial” from November to December with LP- LP-LDL® (LPGOS) cholesterol lowering strain. The pilot trial is essentially a test period where OptiBiotix provide the ingredients for the manufacturing process for the plant in readiness to optimise the production process ahead of the full scale up, it is not to be confused with a soft launch, like we had with SlimBiome. Which brings me nicley on to the fact many have missed – this deal is in addition to the one announced in December 2016 for SlimBiome, this is very much game on and a clearly and added bonus andding further credibility if ever it was needed. It is also worth noting OptiBiotix are essentially putting TATA on trial, similarly to the SACCO agreement, whereby SACCO were granted European license, proved their worth and were rewarded with a global license. For now, TATA will launch a range of food and and over the counter supplements containing LP-LDL® (LPGOS) for the Indian market and then roll-out globally. Today's announcement poses a question about TATA's recent launch of its own healthy option foods containing Fossence™ (Fructo-Oligosaccharide) is a 100 percent soluble, naturally sweet, prebiotic dietary fiber widely used for sugar replacement, fiber fortification with prebiotic properties, as highlighted by Parob. It appears OPTI's LP-LDL (LPGOS) superior health benefits and TATA may be looking to replace Fossence™ for OPTI's LP-LDL® strain (LPGOS). TATA already have a wide range of food products containing Fossence™ and I guess with a greatly increased margin (already high) post the SACCO deal, I would imagine the new deal with SACCO gives OPTI a much more competitive edge on pricing and supply of raw ingredient, not to mention a superior science with functionality. It is clear TATA are expanding its presence in this area and it should be noted OptioBiotix are the only company with a GOS which has a recognised specific health benefit (reducing cholesterol) so this fits their strategic intent and their existing network of distributors and global reach. Pilot was a term introduced by the lawyers as scale up goes through different levels whereby you increase the volumes produced whist optimising the conditions to enhance yield; Its legally correct but clearly TATA are unlikely to sign this off unless they had the ability to take to full scale manufacture as this typically requires an investment of £500k-£750K. hTTps://goo.gl/4UCKwi

You misunderstand the wording. ATA will be running one month “pilot trial” from November to December with LP- LP-LDL® (LPGOS) cholesterol lowering strain. The pilot trial is essentially a test period where OptiBiotix provide the ingredients for the manufacturing process for the plant in readiness to optimise the production process ahead of the full scale up, it is not to be confused with a soft launch, like we had with SlimBiome. Which bring me nicely to the fact this announcement is for OptiBiotix's LP-LDL® (LPGOS) and NOT as per the original agreement for SlimBiome. This is the expansion to the original agreement I mentioned a few weeks ago. SlimBiome/TATA agreement is yet to be announced.

Fair points, to a point. Lets ignore " imo as i feel steadier sustainable share growth can be obtained elsewhere" because we have all made the same mistake....sold a company after it has had a good run, or become stagnant and plough it into seemingly better short term options, only to find the one you sold gained a second, third wind and the one with potential tanked. What you get with OPTI is pretty much a derisked new science, which is gaining global credibility with companies like SACCO and TATA. A company with a mere £95k pm plc cost, CEO and family with skin in the game, warrants that are only awarded once £m's in sales are secured, the potential for a much more diversified portfolio with each spin-out for the patient investors at no additional cost. How many companies do you know that have partners that will fund new development, pay to sit at the table, have multiple products, multiple territories and a growing number of partners, both small and large Few I would imagine. OPTI have a growing strain bank, which can be used with new and existing ingredients, as well as crossover value within the strain family. If there is a company on any index worth being overweight in, it is OPTI.

Then Korg is a bigger fool than he already demonstrates. It is extremely unlikely Korg can influence anyone either way. First he must demonstrate knowledge and respect based on that knowledge without integrity being in question. Korg has merely demonstrated he is not alone in his ignorance of what it takes to go from startup, commercialising new science, rolling out new products, each developing multiple revenue streams with a minimum cost base where partners actually foot the bill....and all in 3 years. Simply banging on about the SP and market cap is pure folly and shows a clear lack of research and foresight. Hey, at least he has people talking about him. I'm sure that's like having a multi bagger in his portfolio :)

Why? You know who they are don't you? I don't expect them to be sold for a while, but hey, what do I know about their financial circumstances.

What financial performance are you talking about? Did you read and UNDERSTAND the profit and loss? Peeps like you always blow their own trumpet....I made x in x and waffle nonsense about market cap like you know what you're talking about. The fact is the markets work on a forward looking basis and investors try to preempt this. You speak nothing of the IP value, nothing of the science, and nothing of very credible partners. You speak nothing about the cost base, or the fact it has just been reduced from /£120k pm to £95k pm. You are just another Michaelmouse, invests in frauds and attempts to come across as some guru while spending his time bashing TW and trolling his tips. Sound familiar? If the cap fits.... Do yourself a favour and look at the Probi model, its revenues and and market cap, then look at industry standards. Then, just for good measure, look at what Probi does and look at what OPTI are about to do. I guess this will seem like too much work for you, but this is how real investors make money.

LOL - Indeed, why diversify your portfolio and invest in a company that commits fraud and insider dealing. No brainer!